In parallel, Peng et al. [130] proposed the use of NRF2 modulators in Barrett’s esophagus, arguing that the progressive increase in ROS and NRF2 activity during malignant transformation could be exploited therapeutically—either through activation in early stages or inhibition once invasive potential emerges. The gene discussed is NFE2L2; the disease is esophageal adenocarcinoma.